The signals received during an infection trigger a strong adaptive immune response tailored to combat a particular class of pathogen. In the presence of cytokines produced by cells of innate immunity, naive CD4^+^ T cells differentiate into a T~H~ cell subset with distinct functions and cytokine profile. Until recently two main T~H~ subsets were described: T~H~1 and T~H~2[@R1]. T~H~1 cells, which predominantly secrete interferon-γ (IFN-γ), are essential for immunity against intracellular microorganisms, while T~H~2 cells, which secrete IL-4, IL-5 and IL-13, are important for protection against parasites and extracellular pathogens. More recently, a third subset of T~H~ cells, called T~H~17, has been described[@R2]--[@R7]. T~H~17 cells produce IL-17A, IL-17F, IL-21 and IL-22, which protect the host against bacterial and fungal infections encountered at mucosal surfaces[@R8]. In mice, T~H~17 differentiation is initiated by the combination of transforming growth factor-β (TGF-β) and IL-6 or IL-21, which induces the expression of retinoic acid receptor-related orphan nuclear receptor, RORγt, and IL-23R[@R7], [@R9]--[@R12]. This acquisition of responsiveness to IL-23 is necessary for the terminal differentiation of the T~H~17 cell lineage and for the maintenance of T~H~17 functions *in vivo*[@R13].

Generally, lineage-specific transcription factors and cytokines can inhibit the differentiation of other T~H~ subsets. T-bet suppresses the generation of T~H~2 cells by blocking the expression of the T~H~2 polarizing cytokine IL-4, and by interfering with the activity of the T~H~2-cell--specific transcription factor, GATA3[@R14], [@R15]. Results from several studies have indicated that T~H~17 responses are stronger in T-bet-deficient animals, although the mechanism underlying this phenomenon was not described[@R16]--[@R19]. This raises the question of whether, analogous to its role in inhibiting the T~H~2 pathway, T-bet also actively suppresses T~H~17 differentiation. Furthermore, several studies have reported that the re-programming of committed T~H~17 and T~H~2 cells into effector cells with T~H~17-T~H~1 and T~H~2-T~H~1 phenotypes is driven by T-bet in response to inflammatory cytokines such as IL-12 and interferons[@R20], [@R21].

In this study we sought to determine whether T-bet plays a regulatory role in the development of the T~H~17 lineage. We investigated T~H~17 differentiationin *Tbx21^−^*^/^*^−^* and WT CD4^+^ T cells *in vitro* and *in vivo* during experimental autoimmune encephalomyelitis (EAE). Here we report that T-bet has a negative effect on the expression of the T~H~17-cell-specific transcription factor RORγt and T~H~17 cytokine genes. Ectopic T-bet expression in naïve T~H~ precursor cells or in committed T~H~17 cells was sufficient to repress the expression of RORγt and T~H~17 signature cytokine genes under T~H~17 polarizing conditions. Mechanistic studies revealed that interaction of T-bet with Runx1 via the T-bet residue Tyr^304^ is critical for blocking Runx1-mediated transactivation of the *Rorc* promoter and for inhibiting T~H~17 lineage commitment.

RESULTS {#S1}
=======

T-bet deficiency promotes IL-17A production *in vitro* {#S2}
------------------------------------------------------

T-bet, encoded by the *Tbx21* gene, is a transcriptional activator of IFN-γ and the key regulator of the T~H~1 differentiation program[@R22]. In addition to promoting differentiation of naive CD4^+^ T cells into the T~H~1 subset, T-bet actively suppresses the development of the T~H~2 lineage [@R14], [@R15]. To investigate whether T-bet expression has a similar antagonistic effect on the development of IL-17A producing T~H~ cells, we cultured *Tbx21^−/−^* and wild-type (WT) CD4^+^ T cells under non-skewing conditions or differentiated them into T~H~1 cells or T~H~17 cells which were grown in the absence or presence of IL-23 (T~H~17 and T~H~17+IL-23 conditions). Since IFN-γ has a negative effect on the polarization of T~H~17 cells and *Tbx21^−/−^* T cells produce significantly less IFN-γ than WT CD4^+^ T cells, *Ifng^−/−^* T~H~ cells were also tested to delineate T-bet- versus IFN-γ-mediated effects on T~H~17 development. After five days of *in vitro* differentiation, *Tbx21^−/−^*, *Ifng^−/−^* and WT T~H~0, T~H~1, T~H~17 and T~H~17+IL-23 cells were briefly stimulated with phorbol myristate acetate and ionomycin (PMA+I). We observed a higher percentage of IL-17A producing cells in T-bet-deficient T~H~0 and T~H~1 cultures when compared to *Ifng^−/−^* and WT cultures ([Fig. 1a](#F1){ref-type="fig"}). Although a similar percentage of IL-17A producing cells was detected under T~H~17 polarizing conditions, the amount of IL-17A secreted by *Tbx21^−/−^* T~H~ cells was higher than that secreted by *Ifng^−/−^* and WT T~H~ cells under all differentiating conditions ([Fig. 1b](#F1){ref-type="fig"}).We did not observe substantial differences in the amount of *Rorc* mRNA expression amongst different T~H~ subsets at 24 hours after activation (data not shown). However, the enhanced IL-17A production by *Tbx21^−/−^* T~H~0 and T~H~1 cultures correlated with a 2-fold increase in the expression of *Rorc* mRNA after 5 days of culture. In contrast, *Tbx21^−/−^*, *Ifng^−/−^* and WT T~H~17 cells expressed similar levels of *Rorc* mRNA ([Fig. 1c](#F1){ref-type="fig"}). These results show that T-bet deficiency promotes development of IL-17A producing cells under all polarizing conditions independently of IFN-γ and suggest that T-bet-mediated effects on the generation of IL-17A producing cells *in vitro* may be through the transcriptional regulation of *Rorc* and/or *Il17a* genes in T~H~0-T~H~1 and T~H~17 cells, respectively.

T~H~17 responses in *Tbx21^−/−^* and WT mice during EAE {#S3}
-------------------------------------------------------

*Tbx21^−/−^* mice are protected from developing EAE[@R23]. At the time when the results of this study were reported, T~H~17 cells were yet to be discovered, and the resistance of *Tbx21^−/−^* mice to central nervous system (CNS)-specific autoimmune attack was ascribed to the polarization shift of CD4^+^ T cells from a pathogenic T~H~1 to a protective T~H~2 response[@R23]. Considering the propensity of T-bet-deficient CD4^+^ T cells to develop into IL-17A-producing cells *in vitro*, we investigated whether *Tbx21^−/−^* mice generated T~H~17 responses during EAE, the pathology of which is widely accepted to be dependent on T~H~17 cells. To determine the types of cytokines produced by CNS-infiltrating CD4^+^ T cells, we performed intracellular cytokine staining on mononuclear cells isolated from the CNS of *Tbx21^−/−^* and WT mice during the peak of disease (day 17 post-immunization). In WT mice, three different cytokine producing populations entered the CNS: those that produced IFN-γ alone (the majority of CD4^+^ T cells), those that produced only IL-17A, and those that produced both cytokines ([Fig. 2a](#F2){ref-type="fig"}). In contrast, in the CNS of *Tbx21^−/−^* mice, IL-17A producing CD4^+^ T cells represented the majority of cytokine producing cells at day 17 post-immunization ([Fig. 2a](#F2){ref-type="fig"}). Consistent with the role of T-bet in controlling expression of the IFN-γ gene, there was a deficiency in IFN-γ-producing CD4^+^ T cells in the CNS of *Tbx21^−/−^* mice ([Fig. 2a](#F2){ref-type="fig"}). Collectively, there was a shift in the T~H~1-T~H~17 balance in the CNS of *Tbx21^−/−^* mice during EAE characterized by the preferential recruitment of T~H~17 cells and significant reduction in the frequency and absolute numbers of IFN-γ-producing CD4^+^ T cells ([Fig. 2b](#F2){ref-type="fig"}). Moreover, CD4^+^ T cells isolated from the CNS of *Tbx21^−/−^* mice secreted significantly higher levels of IL-17A than WT CD4^+^ T cells at day 17 post-immunization ([Fig. 2c](#F2){ref-type="fig"}). Thus, there is a strong recruitment of IL-17A-secreting T~H~17 cells into the CNS of *Tbx21^−/−^* mice.

IL-23R signaling drives the pathogenic potential of CNS-infiltrating T~H~17 cells by promoting the expression of proinflammatory chemokines and by suppressing the expression of IL-10^4^, [@R24]. In addition, IL-23R signaling is essential for the terminal differentiation of T~H~17 cells and their long term survival[@R13], [@R25]. To address the role of T-bet in controlling IL-23R expression in T~H~17 cells, we crossed IL-23R.GFP reporter mice onto a T-bet-deficient background. On day 17 after MOG~35--55~ plus CFA immunization, mononuclear cells were isolated from the draining lymph nodes, spleen and CNS of *Tbx21^−/−^*-IL-23R.GFP and WT-IL23R.GFP reporter mice and the percentage of IL-23R positive cells within the CD4^+^ population was determined by flow cytometry. As shown in [Fig. 2d](#F2){ref-type="fig"}, *Tbx21^−/−^* mice displayed a higher percentage of IL-23R^+^ CD4^+^ cells in the lymph nodes and the CNS versus controls, while in spleen the frequency of IL-23^+^ CD4^+^ T cells was similar. In addition, there was a significantly higher percentage of CD4^+^ cells expressing the T~H~17-specific chemokine receptor, CCR6 in the lymph nodes and the CNS of *Tbx21^−/−^* mice ([Fig. 2d](#F2){ref-type="fig"}). We looked at the expression of other T~H~17 signature genes in purified CD4^+^ T cells isolated from the CNS of *Tbx21^−/−^* and WT mice during the disease peak and observed higher levels of *Rorc*, *Il23r*, *Il17a* and *Il17f* transcripts in *Tbx21^−/−^* CD4^+^ T cells, while the levels of *Il21* and *Il22* were more variable between *Tbx21^−/−^* and WT mice ([Fig. 2e](#F2){ref-type="fig"}). The enhanced Type 17 response in *Tbx21^−/−^* mice could be intrinsic to the T cell or reflect differences in cytokine production by innate immune cells which could create a milieu more conducive for the polarization of T~H~17 cells *in vivo*. To differentiate between these two possibilities we performed functional analysis of CD4^+^ T cells in the CNS of *Tbx21^F/F^* and *Tbx21^F/F^ Cd4*^cre^ mice 14 days after EAE induction ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). Our data demonstrate that T cell-specific deletion of T-bet results in an augmented T~H~17 response in the CNS during EAE, suggesting that this is a T cell-intrinsic phenomenon. Thus, a dominant T~H~17 response is generated in *Tbx21^−/−^* mice following MOG~35--55~ plus CFA immunization, suggesting that T-bet expression limits the magnitude of Type 17 responses in the CNS during EAE.

T-bet expression blocks T~H~17 differentiation {#S4}
----------------------------------------------

The experiments described above suggest strongly that T-bet negatively regulates T~H~17 cell lineage commitment. To directly assess whether T-bet plays a negative role in T~H~17 differentiation, naïve CD4^+^ T cells (CD62L^hi^CD25^lo^) were activated under T~H~17 polarizing conditions. After 24 h, activated CD4^+^ cells were transduced with empty retrovirus (EV-RV) or T-bet-RV containing T~H~17 skewing cytokines + neutralizing IL-4 and IFN-γ antibodies. After 5 days of culture under T~H~17 polarizing conditions, the cytokine production by sorted GFP^+^ cells was determined by intracellular cytokine staining (ICS). Transduction of both *Tbx21^−/−^* and WT naïve CD4^+^ T cells with T-bet resulted in a substantial decrease in the percentage of IL-17A producing cells and a marked increase in the frequency of IFN-γ-IL-17A double producers and IFN-γ single producers ([Fig. 3a](#F3){ref-type="fig"}). T-bet expression resulted in a marked reduction of *Rorc* and *Rorc*-target genes (*Il17a* and *Il17f*), *Il21* and *Il23r* ([Fig. 3b](#F3){ref-type="fig"}). Although we observed no significant difference in the amount of *Il22* transcripts between *Tbx21^−/−^* and WT T~H~17 cells, T-bet over-expression augmented *Il22* mRNA expression in both *Tbx21^−/−^* and WT T~H~17 cells ([Fig. 3b](#F3){ref-type="fig"}). Ectopic expression of T-bet therefore prevents differentiation of T~H~ precursors into T~H~17 cells under T~H~17 polarizing conditions by blocking the expression of the T~H~17 cell lineage-specific transcription factor, RORγt and consequently, RORγt-target genes.

In a separate series of experiments, we utilized the transgenic inducible T-bet expression system, where T-bet is induced in naïve T~H~ precursors in response to doxycycline treatment. Naïve CD4^+^ T cells were activated under T~H~17 polarizing conditions for 24 h. On the second day, T-bet expression was induced by the administration of 0.5 μg/ml of doxycycline in the absence or presence of neutralizing IFN-γ antibody. The amount of RORγt and T-bet mRNA and protein was determined by real-time PCR and immunoblotting, respectively. Induction of T-bet expression in transgenic T~H~ precursors by doxycycline treatment resulted in marked reduction of both RORγt transcripts and protein under T~H~17 polarizing conditions ([Fig. 3c--d](#F3){ref-type="fig"}). We observed suppression of RORγt by T-bet even in the presence of neutralizing IFN-γ antibody demonstrating that this mode of RORγt suppression is independent of IFN-γ.

T-bet can redirect fully differentiated T~H~2 cells into the T~H~1 pathway[@R22]. To determine whether T-bet could similarly reprogram committed T~H~17 cells, we differentiated naïve CD4^+^ T cells (CD62L^hi^CD25^lo^) under T~H~17 polarizing conditions for 6 days after which *Tbx21^−/−^* and WT T~H~17 cells were re-activated for 24 h and transduced with either EV-RV or T-bet-RV under T~H~17 polarizing conditions. Forty-eight hours after retroviral transduction, GFP^+^ cells were sorted and intracellular cytokines examined. There was a 50% reduction of IL-17A producing cells and an increase in the frequency of IFN-γ-producing cells after transduction with T-bet-RV ([Fig. 3e](#F3){ref-type="fig"}). Similar to the experiments above, enforced T-bet expression in fully differentiated T~H~17 cells resulted in reduced levels of *Rorc*, *Il17a*, *Il17f*, *Il21* and *IL23r* transcripts and increased expression of *Il22* ([Fig. 3f](#F3){ref-type="fig"}). These results indicate that ectopic expression of T-bet is sufficient to suppress expression of the Type 17 signature genes in committed T~H~17 cells even in the presence of T~H~17 polarizing cytokines.

T-bet inhibits Runx1 activity {#S5}
-----------------------------

Our results support the idea that the negative effect of T-bet on T~H~17 differentiation could be mediated by inhibition of the T~H~17-cell-specific transcription factor RORγt. To determine whether T-bet binds to the *Rorc* promoter, we performed chromatin immunoprecipitation (ChIP) assays on T-bet-bound chromatin from nuclear lysates of non-polarized T~H~0 cells and differentiated T~H~1 and T~H~17 cells. We detected modest, but reproducible, binding of T-bet to a site located approximately 2kb upstream of the first exon of *Rorc* (the thymus-specific isoform) in non-skewed T~H~0 cells, and we found marked enrichment of T-bet bound to the same -2kb site in T~H~1 cells ([Fig. 4a--b](#F4){ref-type="fig"}). We did not detect binding of T-bet to the *Rorc* or *Ifng* promoter in T~H~17 cells (data not shown). To test whether T-bet directly inhibits *Rorc* gene expression, we performed reporter luciferase assays with the −2kb *Rorc*-luc promoter in HEK293 cells. Transfection of T-bet had no effect on *Rorc*-luc activity indicating that T-bet might not directly suppress *Rorc* transcription ([Fig. 4c](#F4){ref-type="fig"}). T-bet generally does not act as a direct transcriptional repressor [@R15], [@R26], [@R27]. Instead, T-bet exerts its negative effect on gene expression by binding to and sequestering transcriptional activators away from regulatory regions[@R15], [@R26]--[@R29]. Runx1 induces RORγt expression[@R30]. There are two Runx1 binding sites immediately upstream of the T-bet binding site (2kb upstream of the first exon of the *Rorc(T)* gene). This finding prompted us to investigate whether T-bet could inhibit RORγt expression by blocking Runx1 transcriptional activity. To analyze the regulation of the *Rorc* gene, HEK293 cells were transfected with a −2kb *Rorc*-luc reporter construct in the presence of increasing concentrations of Runx1 plasmid with or without T-bet expression vector. Runx1 expression increased luciferase activity in a dose-dependent manner, which was blocked by co-expression of T-bet ([Fig. 4c](#F4){ref-type="fig"}). Furthermore, T-bet blocked Runx1-mediated transactivation of the *Rorc* promoter in a dose-dependent manner ([Fig. 4d](#F4){ref-type="fig"}). Several other transcription factors, namely Irf4, Batf and STAT3, control T~H~17 differentiation by positively regulating *Rorc* expression[@R31]--[@R33]. Relative expression of *Irf4* and *Batf* was similar in *Tbx21^−/−^* and WT T~H~ cells as determined by RT-PCR ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). It is currently unknown whether regulation of *Rorc* expression by Irf4 and Batf is mediated by direct binding of these transcription factors to the *Rorc* locus, but the binding sites for STAT3 in the *Rorc* and *Il17a* loci have been clearly defined[@R33]. To determine whether there was a difference in the binding of STAT3 to its target sequences in the *Rorc* and *Il17a* loci, we performed ChIP on STAT3-bound chromatin from nuclear lysates of non-polarized T~H~0 and T~H~17 cells. The binding of STAT3 to its target sites in the intergenic or intragenic regions of the *Rorc* locusor *Il17a* locus was similar in *Tbx21^−/−^* and WT T~H~0 and T~H~17 cells ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). These data suggest that interference with Runx1, but not STAT3, transcriptional activity is the likely mechanism by which T-bet blocks the expression of RORγt.

T-bet interacts with Runx1 {#S6}
--------------------------

To examine further the mechanism of T-bet-mediated repression of *Rorc* expression, we investigated whether T-bet could interact with Runx1. First, we over-expressed T-bet with Myc-tagged Runx1, Runx2 and Runx3 and performed co-immunoprecipitation experiments in HEK293 cells. T-bet interacted with both Runx1 and Runx3, but not Runx2 in HEK293 cells ([Fig. 5a](#F5){ref-type="fig"}). To determine in which T~H~ subset T-bet and Runx1 interact, we performed immunoblot analysis of Runx1 and T-bet protein expression in unskewed T~H~0 and differentiated T~H~1 and T~H~17 cells. We detected T-bet and Runx1 expression in non-polarized T~H~0 cells ([Fig. 5b](#F5){ref-type="fig"}). There was a marked reduction in the expression of Runx1 protein in *in vitro* differentiated T~H~1 cells and conversely, a marked decrease in levels of T-bet protein in *in vitro* differentiated T~H~17 cells ([Fig. 5b](#F5){ref-type="fig"}). These data suggest that interaction between T-bet and Runx1 could occur in non-polarized T~H~0 cells in which both proteins are co-expressed. Indeed, Runx1 immunoprecipitation confirmed the presence of an endogenous T-bet-Runx1 interaction in non-polarized WT T~H~0 cells, but not in differentiated T~H~1 and T~H~17 cells ([Fig. 5c](#F5){ref-type="fig"} and data not shown). T-bet-Runx1 interaction in uncommitted T~H~0 cells was also confirmed in the reverse co-immunoprecipitation assay ([Fig. 5c](#F5){ref-type="fig"}). These data suggest that a functionally important interaction between T-bet and Runx1 most likely occurs in uncommitted T~H~ cells, but not in fully differentiated T~H~1 and T~H~17 cells because of restrictive expression of Runx1 and T-bet, respectively, in these T~H~ cells.

Based on the luciferase data and co-immunoprecipitation experiments, one could hypothesize that T-bet interaction with Runx1 could block Runx1 binding to its consensus sites located -2kb in the *Rorc(T)* promoter . We detected Runx1 binding to the oligo containing the WT Runx1 target sequence, but not to the oligo in which the Runx1 target sequence was mutated by a T to A substitution ([Fig. 5d](#F5){ref-type="fig"}). T-bet bound to the WT oligo containing a T-bet specific half-site, but not to the oligo in which the T-bet half-site was mutated ([Fig. 5d](#F5){ref-type="fig"}). After confirming that Runx1 and T-bet binding to the -2kb *Rorc(T)* site was sequence-specific, we performed a DNA pull-down assay with the WT oligo and Runx1 in the absence or presence of increasing concentrations of T-bet. In the absence of T-bet, Runx1 bound strongly to the DNA oligo containing the WT Runx1 binding site ([Fig. 5e](#F5){ref-type="fig"}). Increasing concentrations of T-bet ablated the ability of Runx1 to bind to its target sequence in a dose-dependent manner showing that T-bet interaction with Runx1 interferes with Runx1 binding to its -2kb *Rorc(T)* site ([Fig. 5e](#F5){ref-type="fig"}).

Runx1 reversed T-bet effects on T~H~17 polarization {#S7}
---------------------------------------------------

Next we investigated whether Runx1 over-expression could block the inhibitory effects of T-bet on T~H~17 differentiation. Purified CD4^+^ T cells were transduced with various combinations of retroviruses expressing GFP alone (EV-GFP), Thy1.1 alone (EV-Thy1.1), Runx1-GFP and/or T-bet-Thy1.1. The transduced cells were grown under T~H~17 conditions for 5 days after which GFP-Thy1.1 double-positive cells were sorted and examined for T~H~17 commitment. Retroviral transduction of T~H~ cells with T-bet had a negative effect on T~H~17 commitment under T~H~17 polarizing conditions, while transduction of T~H~ cells with Runx1 augmented the differentiation of T~H~17 cells ([Fig. 6a--b](#F6){ref-type="fig"}). Over-expression of Runx1 reversed the inhibitory effect of T-bet and fully restored T~H~17 polarization in cells co-expressing Runx1 and T-bet (EV vs. T-bet-Runx1). However, *Rorc* expression was only partially up-regulated, suggesting that there may be additional mechanism(s) by which T-bet inhibits transcription of the *Rorc* gene in T~H~17 cells ([Fig. 6b](#F6){ref-type="fig"}). Conversely, transduction of purified *Tbx21^−/−^* CD4^+^ T cells with Runx1 dominant negative (DN) retrovirus during T~H~17 differentiation reversed the effects of T-bet deficiency on IL-17A production by T~H~17 cells ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}).

In addition to directly promoting RORγt expression, Runx1 also acts as a co-activator and together with RORγt induces the expression of the *Il17a* and *Il17f* genes[@R30]. T-bet suppresses T~H~17 differentiation by inhibiting the expression of the *Rorc* gene ([Fig. 3](#F3){ref-type="fig"}). However, it is possible that T-bet's interaction with Runx1 serves to sequester this transcriptional co-activator and blocks the expression of T~H~17 signature genes in this manner. To investigate this possibility, we asked whether RORγt was able to restore a T~H~17 developmental program in T~H~ cells co-expressing T-bet and RORγt under T~H~17 polarizing conditions. Expression of RORγt independently of the T-bet transcriptional block (i.e. from the retroviral LTR control elements) in developing T~H~17 cells was unable to fully reverse the T-bet mediated inhibition of T~H~17 differentiation ([Fig. 6c--d](#F6){ref-type="fig"}). We were unable to co-immunoprecipitate T-bet and RORγt in 293HEK cells, suggesting that the sequestration of RORγt from its target genes by T-bet is unlikely. These data demonstrate that in addition to inhibiting the transcription of the *Rorc* gene, T-bet interaction with Runx1 depletes the pool of free Runx1 which is available for the formation of transcriptionally active Runx1-RORγt complexes in T~H~17 cells.

T-bet Tyr^304^ is crucial for suppression of T~H~17 cells {#S8}
---------------------------------------------------------

To investigate which amino-acid residue is important for T-bet-Runx1 complex formation, we tested the ability of a series of T-bet mutants to interact with Runx1 in HEK293 cells. Two of these point mutants, T-bet~S508A~ and T-bet~Y525F~, were shown previously to be functionally important in IL-2 and in T~H~2 lineage suppression, respectively[@R15], [@R27]. Coimmunoprecipitation studies revealed that Runx1 interacted with the T-bet~Y265F~, T-bet~S508A~ and T-bet~Y525F~ mutants, but not with the T-bet~Y304F~ mutant ([Fig. 7a](#F7){ref-type="fig"}). Furthermore, the T-bet~Y304F~ mutant was unable to suppress Runx1 transcriptional activity in the -2kb *Rorc*-luciferase assay ([Fig. 7b](#F7){ref-type="fig"}) suggesting that this T-bet Tyr^304^ residue may be important for the suppression of T~H~17lineage commitment. To answer this question, sorted naïve T~H~ cells were activated under T~H~17 polarizing conditions for 24 h and transduced with control, WT T-bet, T-bet~Y304F~ and T-bet~Y525F~ mutant retroviruses. The transduced cells were cultured under T~H~17 polarizing conditions for an additional 5 days and the percentage of IFN-γ and IL-17 producing cells was determined by ICS. WT T-bet and the T-bet~Y525F~ control mutant suppressed T~H~17differentiation under T~H~17 polarizing conditions. In contrast, mutation of T-bet residue Tyr^304^ abrogated the ability of T-bet to repress T~H~17 lineage commitment ([Fig. 7c](#F7){ref-type="fig"}). When compared with WT T-bet and the T-bet~Y525F~ mutant, the T-bet~Y304F~ mutant was unable to suppress expression of *Rorc*, *Il17a*, *Il17f* and *Il23r* in developing T~H~17 cells ([Fig. 7d](#F7){ref-type="fig"}). These data indicate that T-bet residue Tyr^304^ is important for T-bet-Runx1 complex formation, for inhibition of Runx1 transcriptional activity and for suppression of T~H~17 lineage development.

In DNA pull-down assays, the T-bet~Y304F~ mutant failed to bind to the T-bet binding site in the -2kb *Rorc(T)* promoter region suggesting that this residue is also important for T-bet binding to DNA ([Fig. 7e](#F7){ref-type="fig"}). To delineate whether T-bet-mediated inhibition of Runx1 activity was dependent on DNA binding or T-bet-Runx1 protein-protein interaction, we investigated whether WT T-bet could inhibit Runx1 binding to its target site using oligos in which the T-bet binding site was mutated. T-bet blocked Runx1 binding to the Runx1-specific sequence independently of T-bet's ability to bind to DNA (lane 3, [Fig. 7f](#F7){ref-type="fig"}). Collectively, these data suggest that the T-bet-Runx1 protein-protein interaction is mainly responsible for inhibition of Runx1 activity with a T-bet protein-DNA interaction playing a minor if any role.

DISCUSSION {#S9}
==========

Lineage-specific transcription factors can both activate and repress differentiation programs. T-bet simultaneously promotes T~H~1 differentiation and represses T~H~2 differentiation [@R3], [@R6]. While several studies have reported an enhanced Type 17 response in *Tbx21^−/−^* animals in different disease models[@R16]--[@R19], no mechanistic explanation for this increase in T~H~17 responses was provided. Here, we demonstrate that T-bet suppresses T~H~17 cell lineage commitment by inhibiting the transcription of the T~H~17-cell-specific transcription factor RORγt and its target genes. T-bet did not directly repress the *Rorc* promoter. Instead, T-bet interacted with the Runx1 transcription factor and blocked Runx1-mediated transactivation of *Rorc*. Over-expression of Runx1 was sufficient to reverse the inhibitory effects of T-bet on IL-17A production by T~H~17 cells. Furthermore, we demonstrate that T-bet residue Tyr^304^ is crucial not only for T-bet-Runx1 complex formation, but also for blocking Runx1 activity and for inhibiting the T~H~17 differentiation program. Thus, our data uncover a molecular mechanism to explain the exaggerated T~H~17 responses observed in T-bet deficient hosts.

In addition to activating a set of genes that promote T~H~ cell differentiation towards a specific lineage, a master regulator can also suppress the developmental program of the opposing T cell lineages[@R34]. Among the T~H~ cell-specific transcription factors, T-bet seems to be particularly active in this regard. The ability of T-bet to negatively regulate the differentiation of T~H~2 cells[@R15], [@R22], IL-2 production from T~H~1 cells[@R27] and tumor necrosis factor (TNF) production in dendritic cells[@R26] prompted us to investigate the contribution of T-bet to the regulation of the T~H~17 response. Our data show that T-bet deficiency results in an augmented Type 17 response *in vitro* and *in vivo* during CNS inflammation in the EAE model of multiple sclerosis. Our results differ from a previous publication which reported that mice injected with T-bet-specific siRNA had lower expression of IL-23R and lacked T~H~17 cells after immunization with myelin basic protein (MBP) Ac~1--11~ plus CFA or MOG~35--55~ plus CFA[@R35], [@R36]. We demonstrate instead that T~H~17 cells are present in the CNS of *Tbx21^−/−^* mice in greater numbers and with strong expression of T~H~17 signature genes after MOG~35--55~ plus CFA induced EAE. The disparity between the two studies may arise from differences in experimental conditions, such as the use of T-bet-specific siRNA rather than complete genetic deletion *in vivo.* In support of our results, other studies also detected a higher frequency of myelin-specific T~H~17 cells in MOG~35--55~ plus CFA immunized *Tbx21^−/−^* mice than WT mice[@R36]. Interestingly, despite a strong T~H~17 response, *Tbx21^−/−^* mice are largely protected from the development of EAE. This observation might be explained by postulating that in the inflammatory milieu of the CNS, T-bet controls expression of a novel set of genes that is important for the pathogenicity, but not for the development of T~H~17 cells. In support of this hypothesis, a recent study reported that T-bet is expressed in IL-23-treated T~H~17 cells and these T-bet-expressing T~H~17 cells were pathogenic during CNS inflammation pointing to the important functional role of T-bet in a subset of T~H~17 cells[@R37]. Alternatively, the presence of both T~H~1 and T~H~17 cells might be required for CNS pathology. Finally, T-bet expression in other cell types might be important for driving disease development.

Here, we have focused on T-bet's function in T~H~17 lineage commitment of CD4^+^ T cells. In this study, we have demonstrated that T-bet over-expression in naïve T~H~ cell precursors or committed T~H~17 cells had a negative effect on *Rorc* transcription and consequently on the expression of *Rorc*-target genes. In addition, we observed downregulation of *Il21* gene expression. T-bet suppressed IL-21 in T~H~1 cells by interacting with NFATc2, thus preventing NFATc2 from binding to the *Il21* promoter[@R29]. Since IL-21 promotes IL-23R expression in T~H~17 cells[@R10], T-bet-mediated suppression of *Il21* could also contribute to reduced levels of *Il23r* in T~H~17 cells after transduction with a T-bet expressing retrovirus. In contrast to *Rorc*, *Il17a*, *Il17f*, *Il23r*, which were suppressed by T-bet, the expression of *Il22* was augmented by ectopic expression of T-bet. The aryl hydrocarbon receptor (AHR) controls IL-22 production by T~H~17 cells, as CD4^+^ T~H~17 cells from AHR-deficient mice fail to produce IL-22 when exposed to AHR ligands[@R38], [@R39]. Thus, it is plausible that T-bet expression has a synergistic effect on AHR-mediated induction of IL-22.

We detected endogenous T-bet binding in the region located 2kb upstream of the first *Rorc* exon in non-skewed and T~H~1 cells, but not T~H~17 cells. Interestingly, differentiation of T~H~ cells down the T~H~1 pathway resulted in markedly reduced expression of Runx1. Conversely, culturing T~H~ cells in the presence of T~H~17-polarizing cytokines resulted in suppression of T-bet protein expression. This is not surprising since TGF-β has a negative effect on T-bet expression, and IFN-γ, the most potent inducer of T-bet expression, is neutralized under *in vitro* T~H~17 polarizing conditions. Thus, the lack of T-bet binding to the *Rorc* promoter in committed T~H~17 cells could be explained by substantially reduced expression of T-bet in this T~H~ subset.

We did not detect any significant effects of T-bet over-expression on *Rorc* promoter activity in luciferase assays. Evidence that T-bet acts as a direct transcriptional repressor or can recruit co-repressors to these promoters is currently lacking. However, T-bet can exert a negative regulatory effect on gene expression by blocking the activity of competing transcription factors[@R15],[@R26], [@R27]. Our understanding of the transcriptional regulation of RORγt is still incomplete. It has been reported that the expression of RORγt is substantially reduced in *Irf4^−/−^* and *Stat3^−/−^* CD4^+^ cells[@R31], [@R40]--[@R42]. Runx1 induces RORγt expression and Batf is important for the maintenance of RORγt expression in stimulated T c ells[@R30], [@R32]. It is currently unknown whether regulation of *Rorc* expression by Irf4 and Batf is mediated by direct binding of these transcription factors to the *Rorc* locus, but the binding sites for STAT3 in the *Rorc* and *Il17a* loci have been identified[@R33]. STAT3 binding to both the *Rorc* and *Il17a* loci was similar between *Tbx21^−/−^* and WT T~H~ cells. Hence, we focused on the transcriptional activity of Runx1 since we detected two Runx1 consensus sites in the proximity of the T-bet peak binding site located -2kb from the first exon of *Rorc* as shown by ChIP.

Based on the protein expression data and co-immunoprecipitation experiments, we propose that the functionally important interaction of T-bet and Runx1 occurs in uncommitted T~H~ cells. We mapped the function of T-bet in interacting with Runx1, repressing Runx1 activity, and suppressing T~H~17 differentiation program to Tyr^304^. Our preliminary data indicate that this tyrosine is not phosphorylated and that the protein is stably expressed in HEK293 cells and primary T cells. In DNA pull-down assays, the T-bet~Y304F~ mutant failed to bind to DNA. Although the Tyr^304^ residue is important for T-bet-DNA interaction, our results indicate that this interaction is not essential for T-bet's ability to block Runx1. WT T-bet was still able to block Runx1 binding to its target site in a RORγt promoter bearing a mutated T-bet half-site. Thus, the T-bet-Runx1 protein-protein interaction is the major mechanism by which T-bet blocks Runx1 activity by sequestering Runx1 away from the RORγt promoter.

In both infectious and autoimmune diseases, T cell-mediated responses are characterized by the presence of cells co-expressing IL-17A and IFN-γ, the so called IFN-γ^+^ T~H~17 cell. T cell clones from MBP-peptide immunized mice were genetically either T-bet^+^-RORγt^−^ or T-bet^+^-RORγt^+^ [@R28]. T-bet^+^-RORγt^+^ cells were very responsive to exogenous cytokines such as IL-12 and IL-23, which influenced the relative levels of T-bet and RORγt, and shifted cytokine production towards IFN-γ or IL-17A, respectively[@R28]. The unstable phenotype of T~H~17 cells is not restricted to CNS-specific autoimmunity. IL-17F reporter mice in a transfer model of colitis demonstrated that IFN-γ-producing CD4^+^ T cells can emerge fromT~H~17 committed cells during T cell driven inflammation. This transition of T~H~17 cells into IFN-γ-producing cells was STAT4- and T-bet-dependent[@R21]. In the context of these recent findings, it is tempting to propose that this T-bet-mediated transition of T~H~17 cells into a "T~H~1-like" subset is controlled partly by T-bet-mediated interference with Runx1 transcriptional activity. Ectopic expression of T-bet in T~H~17 cells results in the suppression of *Rorc*. However, in fully differentiated T~H~17 cells, which already express RORγt, T-bet could still interfere with RORγt transcriptional activity by sequestering its co-activator, Runx1. Thus, over-expression of Runx1 in T~H~17 cells overcame the inhibitory effect of T-bet and completely restored IL-17A production. Although Runx1 fully restored IL-17A production, the expression of *Rorc* was only partially increased. These results indicate that there are additional mechanism(s) by which T-bet inhibits *Rorc* gene expression. One potential mechanism could be via IL-12 signaling inducing repressive epigenetic changes of the *Rorc* locus, which are dependent on T-bet and STAT4[@R43]. Thus, T-bet re-expression in T~H~17 cells turns off RORγt expression through the sequestration of Runx1 and through the introduction of epigenetic changes resulting in expression of T~H~1 signature genes and acquisition of the "T~H~1- like" phenotype by T~H~17 cells.

METHODS {#S10}
=======

Mice {#S11}
----

*Tbx21^−/−^*, *Tbx21^−/−^* IL-23R.GFP and IL-23R.GFP mice (all C57BL/6 background) were housed at Harvard School of Public Health and were handled in accordance with guidelines from the Center for Animal Resources and Comparative Medicine (ARCM) at Harvard Medical School. *Tbx21^−/−^* rtTA^+^ TrTB^+^ mice were housed at College of Pharmacy; Ewha Womans University, Soul, S. Korea. *Ifng^−/−^* mice were purchased from Jackson Laboratories. *Cd4^cre^* and *Tbx21^F/F^* mice were provided by Dr. Christopher B. Wilson (The Bill and Melinda Gates Foundation) and Dr. Steven L. Reiner (the University of Pennsylvania), respectively.

Plasmids {#S12}
--------

Constitutively active STAT3 (pRc/CMV STAT3-C) was obtained from Addgene (submitted by Dr. J.E. Darnell)[@R44]. pMCsIg-EV, pMCsIg-Runx1 and pMCsIg-Runx1-DN retroviral plasmids were generously provided by Dr. Warren Strober (NIAID, NIH).

CD4^+^ T helper differentiation *in vitro* {#S13}
------------------------------------------

*Tbx21^−/−^*, *Ifng^−/−^* and WT CD4^+^ T cells were stimulated for 48 h with anti-CD3 antibody (2 μg/ml) in the presence of irradiated splenocytes at a ratio of 5:1. CD4^+^ T cells were cultured under T~H~0 conditions (200 U/ml of hIL-2; NCI BRB Preclinical Repository) or differentiated into T~H~1 cells with hIL-2 (200 U/ml), mIL-12 (10 ng/ml; Peprotech) and anti-mIL-4 antibody (10 μg/ml; clone 11B11; BioXCell) or into T~H~17 cells by the addition of hTGF-β (2 ng/ml; R&D Systems), mIL-6 (20 ng/ml; R&D Systems), anti-mIL-4 (10 μg/ml) and anti-mIFN-γ (10 μg/ml; clone XMG1.2; BioXCell) antibodies for 5 days. T~H~17+IL-23 cells were cultured in the presence of hTGF-β, mIL-6, anti-IL-4 and anti-IFN-γ antibodies for the first 48 hours of activation after which T~H~17 cells were cultured in the presence of IL-23 (10 ng/ml; R&D Systems).

Isolation and functional analysis of CNS mononuclear cells {#S14}
----------------------------------------------------------

EAE was induced in 8 -- 10 week old mice as described previously[@R23]. CNS-infiltrating cells were re-stimulated with PMA+I for 4 h before performing intracellular cytokine staining for IFN-γ (XMG1.2; BD Pharmingen)and IL-17A (TC11-18H10; BD Pharmingen). For ELISA and RT-PCR analysis, CNS-derived CD4^+^ T cells were purified using CD4 negative selection kit (Stem Cell Technologies). Purified CD4^+^ T cells (\>95% purity) were pooled from 4--5 mice/group and cells were stimulated for 4 h with PMA+I. The RT-PCR primer sequences are listed in the [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Retroviral transduction {#S15}
-----------------------

Naïve (CD62L^hi^CD25^lo^) CD4^+^ T cells were transduced with indicated retroviruses 24 h after activation. Transduced cells were cultured for 5 days under T~H~17 conditions, and the sorted GFP^+^ cells were tested for cytokine production after 4 h of PMA+I stimulation. For transduction of committed T~H~17 cells, naïve CD4^+^ T cells were cultured under T~H~17 conditions for 6 days. T~H~17 cells were activated on plate-bound anti-CD3/CD28 plates and transduced with retroviruses for 24 h under T~H~17 conditions. Transduced cells were cultured for additional 48 h under T~H~17 conditions. The sorted GFP^+^ were stimulated with PMA+I for 4 h prior to functional analysis.

Doxycycline inducible T-bet transgenic T~H~17 *in vitro* cultures {#S16}
-----------------------------------------------------------------

Twenty-four hours after anti-CD3/CD28 activation, T-bet was induced in T~H~ cells by the addition of 0.5 μg/ml of doxycycline to the T~H~17 culture media. Twenty-fours after T-bet induction with doxycycline, lysates were analyzed for the expression of *Tbx21* and *Rorc* by RT-PCR. In addition, cells were immunoblotted with anti-T-bet and anti-RORγt antibody (clone B2D; eBioscience).

ChIP {#S17}
----

Naïve cells were sorted from spleens and lymph nodes of *Tbx21^−/−^* and WT mice and differentiated under T~H~0~,~ T~H~1 and T~H~17 polarizing conditions as described above. Differentiated T~H~ cells were used in ChIP assay after 6 h PMA+I stimulation. The ChIP assay was performed as described previously[@R45]. The primers sets used for real-time PCR to quantitate the ChIP enriched DNA are listed in the [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.The antibodies used for ChIP were polyclonal rabbit anti-T-bet (clone 9856) and anti-Stat3 (C-20; Santa Cruz) antibodies.

Luciferase assays {#S18}
-----------------

The mouse *Rorc(T)* promoterwas cloned into pGL3-basic plasmid upstreamof the firefly luciferase gene (Promega). To study the effects of T-bet and Runx1 on the *Rorc* promoter activity, HEK293 cells were transfected with *Rorc-*luc plasmid, increasing concentrations of Runx1,T-bet or pCDNA3.1- (empty vector control) and pRL-TK (Promega) using Fugene (Roche). To determine the dose-dependent effect of T-bet on Runx1 activity, HEK293 cells were transfected with *Rorc-*luc plasmid, Runx1, increasing concentration of T-bet and pRL-TK. Fireflyand *Renilla* luciferase activities were measured 48 h aftertransfection with the Dual Luciferase System (Promega).

Coimmunoprecipitation {#S19}
---------------------

HEK293 cells were transiently transfected with WT T-bet, or T-bet point mutants, Myc-Runx1 or empty vector using Fugene (Roche). 48 h after transfection, cells were lysed in TNT lysis buffer (1% triton X-100, 50mM Tris pH 7.5, 200mM NaCl, 1mM DTT, protease and phosphatase inhibitors). For endogenous Runx1 and T-bet coimmunoprecipitations, 3\~4×10^8^ of differentiated T~H~0, T~H~1 and T~H~17 cells were stimulated for 6 h with PMA+I after which cells were lysed in TNT lysis buffer. Whole cell lysates were immunoprecipitated withthe anti-Runx1 antibody (ab23980; Abcam) or IgG and protein A-sepharose coupled beads at 4°C. Immune complexes were immunoblotted using polyclonal rabbit anti-T-bet antibody. In the reverse co-immunoprecipitation assay, T-bet was immunoprecipitated using polyclonal rabbit anti-T-bet antibody (H-210; Santa Cruz) and separated immune complexes were immunoblotted with polyclonal rabbit anti-Runx1 antibody (ab23980; Abcam). To minimize interference of Runx1 or T-bet detection by the heavy chains of the immunoprecipitating T-bet, Trueblot ULTRA kit (eBioscience) was used for interaction analysis of Runx1 with T-bet in the reverse co-immunoprecipitation assay.

DNA binding assay {#S20}
-----------------

DNA binding assay was performed as described previously[@R46]. HEK293 cells were transfected with Myc-Runx1 expression plasmid in the absence or presence of increasing concentrations of T-bet expression vector. 150 μg of nuclear protein was incubated with 50 nt biotinylated probe containing wild-type, mutant T-bet binding site or mutant Runx1 binding site \[− 2kb of exon 1 encoding *Rorc(T)*\] plus streptavidin-agarose (Invitrogen) for 1 hour at 4°C in Binding buffer (100 mM NaCl, 10 mM Tris-HCl pH 7.6, 0.1 mM EDTA, 1 mM DTT, 5% glycerol, 1 mg/ml BSA, 20 μg/ml poly dI/dC plus protease inhibitors). Streptavidin-beads were washed in Binding buffer, and bound proteins were immunoblotted for over-expressed Myc-Runx1 and T-bet.
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![T-bet deficiency promotes IL-17A production *in vitro* independently of IFN-γ. (**a**) Flow cytometry analyzing the IL-17A and IFN-γ production following 4 h stimulation with phorbol ester + ionomycin (PMA+I). *Tbx21^−/−^*, *Ifng^−/−^* and wild-type CD4^+^ T cells were cultured in the presence of IL-2 (T~H~0 cells), IL-2 + IL-12 + anti-IL-4 antibody (T~H~1 cells), TGF-β + IL-6 + anti-IL-4 + anti-IFN-γ antibodies (T~H~17 cells) or TGF-β + IL-6 + anti-IL-4 + anti-IFN-γ antibodies followed by IL-23 treatment (T~H~17+IL-23 cells). Following five days of *in vitro* differentiation, T~H~ cells were stimulated with PMA+I for 4 hours prior to intracellular cytokine staining with anti-IL-17A and anti-IFN-γ antibodies. (**b)** The amount of IL-17A in the supernatants of PMA+I stimulated T~H~0, T~H~1 and T~H~17 and T~H~17+IL-23 cells was determined by ELISA. The data are representative of four independent experiments (**a--b**). (**c**) *Rorc* mRNA expression in *Tbx21^−/−^* and WT T~H~0, T~H~1 and T~H~17 and T~H~17+IL-23 cells was determined by RT-PCR after 4 h stimulation with PMA+I. The data represent mean ± s.e.m. of two independent experiments.](nihms261541f1){#F1}

![T-bet deficiency promotes T~H~17 responses in the CNS during EAE. (**a**) IL-17A and IFN-γ production by CNS-infiltrating CD4^+^ lymphocytes on day 17 post-immunization with MOG~35--55~ plus CFA. Numbers illustrate the percent positive cells in the CD4^+^ gate. (**b**) Quantification of IL-17A- and IFN-γ producing CD4^+^ cells in the CNS of *Tbx21^−/−^* and WT mice on day 17 post-immunization. (**c**) IL-17A and IFN-γ produced by purified CNS-infiltrating CD4^+^ T cells as determined by ELISA. The concentration of cytokines was normalized to 1×10^6^ cells/ml. The bars represent mean ± s.e.m. of three independent experiments. (**d**) Cells were prepared from *Tbx21^−/−^* IL-23R.GFP and WT-IL-23R.GFP mice on day 17 after EAE induction and analyzed by flow cytometry. Graphs summarize IL-23R and CCR6 expression (percent of the CD4^+^ gate) in three independent experiments (n=3--4 mice per group in each experiment). (**e**) Expression of T~H~17 signature genes in CD4^+^ T cells purified from the CNS of *Tbx21^−/−^* and WT mice on day 17 post-immunization. Cells were pooled from 4 mice per group and were stimulated with PMA+I for 4 h before RNA extraction. The bars represent mean ± s.e.m. of three independent experiments. Statistical analysis was performed using Student-t test; \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.0001.](nihms261541f2){#F2}

![T-bet expression in naïve T~H~ precursors and fully differentiated T~H~17 cells inhibits T~H~17 response. (**a**) Flow cytometry of IL-17A and IFN-γ expression by naïve CD4^+^ T cells transduced with empty retrovirus or T-bet expressing retrovirus under T~H~17 polarizing conditions. Intracellular cytokine staining was performed on sorted GFP^+^ cells after a 4 h PMA+I stimulation. (**b**) Real-time PCR analysis of *Rorc*, *Il23r*, *Il17a*, *Il17f*, *Il21* and *Il22* mRNA expression in naïve CD4^+^ T cells transduced with empty retrovirus or T-bet expressing retrovirus under T~H~17 polarizing conditions. (**c**) *Tbx21* and *Rorc* mRNA expression and (**d**) T-bet and RORγt protein expression in untreated and doxycyline treated *Tbx21^−/−^* rtTA^+^TrTB^+^ transgenic T~H~ precursor cells activated under T~H~17 polarizing conditions in the absence or presence of anti- IFN-γ antibody. (**e**) Flow cytometry of IL-17A and IFN-γ expression by fully differentiated T~H~17 cells transduced with empty retrovirus or T-bet expressing retrovirus under T~H~17 polarizing conditions. Intracellular cytokine staining was performed following a 4 h PMA+I stimulation. (**f**) Real-time PCR analysis of T~H~17 signature genes in fully differentiated T~H~17 cells transduced with empty retrovirus or T-bet expressing retrovirus in the presence of T~H~17 polarizing cytokines. The data in (**a--f**) are representative of three independent experiments.](nihms261541f3){#F3}

![T-bet blocks Runx1-mediated transactivation of the *Rorc* promoter. (**a--b**) T-bet binding to the *Rorc* promoter in T~H~0 and differentiated T~H~1 cells after 6 h PMA+I stimulation, as assessed by ChIP. In all experiments, the *Ifng* promoter and *Il4* promoter were included as positive and negative controls, respectively. As specificity controls, ChIP was performed using pre-immune serum and *Tbx21^−/−^* cells. Fold enrichment was calculated by determining the ratios of the amount of immunoprecipitated DNA tothat of the input sample. The ChIP assays were repeated three times. (**c**) *Rorc* reporter plasmid was constructed from a 2 kb fragment of the mouse *Rorc* promoter. HEK293 cells were transfected with empty pGL3 basic plasmid or *Rorc*-luc reporter construct, pRL-TK, increasing concentration of Runx1 in the absence or presence of T-bet. (**d**) HEK293 cells were transfected with the *Rorc*-luc reporter construct, pRL-TK, Runx1 in the absence or presence of increasing concentration of T-bet. Luciferase activity was measured by Dual Luciferase reporter assay and relative luciferase activity was normalized to pRL-TK for transfection efficiency and empty vector control. Bars represent mean ± s.e.m. of duplicate samples. The graphs are representative of three (**c**) and two (**d**) independent experiments.](nihms261541f4){#F4}

![T-bet interacts with Runx1. (**a**) HEK293 cells were transfected with empty vector, T-bet and Myc-tagged Runx1, Runx2 and Runx3 expression vectors as indicated. Lysates were immunoprecipitated with anti-T-bet polyclonal antibody followed by immunoblotting with anti-Myc antibody. (**b**) Runx1 and T-bet protein expression in *Tbx21^−/−^* and WT T~H~0, T~H~1 and T~H~17 cells after 6 h stimulation with PMA+I. (**c**) Endogenous interaction between Runx1 and T-bet in non-polarized T~H~0 cells. Cell lysates of *Tbx21^−/−^* and WT T~H~0 cells were immunoprecipitated with a control, anti-Runx1 or anti-T-bet antibodies and immunoblotted with anti-T-bet or anti-Runx1 antibody. (**d**) A DNA pull-down assay with a Wt oligo (containing wild-type Runx1 and T-bet binding sites), R-mt oligo (containing mutated Runx1 binding site) or T-mt oligo (containing mutated T-bet binding site) in the presence of Myc-Runx1 or T-bet. (**e**) 293HEK cells were transfected with a Wt or R-mt oligo and Runx1 in the absence or presence of increasing doses of T-bet (0.1, 0.5 and 1 μg). Oligo-bound proteins were immunoblotted for over-expressed Myc-Runx1 and T-bet. The data are representative of one - two independent experiments.](nihms261541f5){#F5}

![Runx1 over-expression restores IL-17A production in T-bet expressing T~H~17 cells. **(a)** CD4^+^ T cells were transduced with retroviruses expressing GFP, Thy1.1, Runx1-GFP and/or T-bet-Thy1.1 within 24 hours of activation. Cells were cultured under T~H~17 polarizing conditions for 5 days and stimulated with PMA+I for 4 h prior to intracellular cytokine staining for IL-17A. Numbers indicate the percentage of IL-17A producing cells within GFP^+^/Thy1.1^+^ gate. **(b)** CD4^+^ T cells were transduced with various combinations of retroviruses as described in (**a**). Following 5 days of *in vitro* differentiation under T~H~17 polarizing conditions, GFP^+^-Thy1.1^+^ cells were sorted and stimulated with PMA+I for 4 h prior to the analysis of IL-17A production and the *Rorc* gene expression. **(c)** Activated CD4^+^ T cells were transduced with retroviruses expressing GFP, Thy1.1, RORγt-GFP and/or T-bet-Thy1.1. The transduced cells cultured under T~H~17 conditions for 5 days were stimulated with PMA+I for 4 h prior intracellular cytokine staining for IL-17A. The numbers indicate percentage of IL-17A producing cells within GFP^+^/Thy1.1^+^ gate. **(d)** Cells were transduced under T~H~17 condition as described in (**c**). IL-17A production was measured by ELISA and RT-PCR and *Rorc* mRNA transcripts were analyzed by RT-PCR. The results in **(a--d)** are representative of two independent experiments.](nihms261541f6){#F6}

![T-bet Tyr^304^ is essential for T-bet-Runx1 interaction and for inhibiting the T~H~17 differentiation program. (**a**) Interaction of Runx1 with WT T-bet or T-bet point mutants in co-immunoprecipitation experiments in HEK293 cells. (**b**) HEK293 cells were transfected with *Rorc*-luc reporter construct, pRL-TK, Runx1 in the absence or presence of WT T-bet or T-bet point mutants as indicated. (**c**) Flow cytometry analyzing IL-17A and IFN-γ expression by naïve CD4^+^ T cells transduced with empty vector, WT T-bet, or T-bet point mutants under T~H~17 polarizing conditions. Numbers in quadrants illustrate the percent positive cells in the CD4^+^ gate. (**d**) RT-PCR analysis of T~H~17 signature genes by CD4^+^ T cells transduced with empty vector, WT T-bet, or T-bet point mutants under T~H~17 conditions. (**e**) 293HEK cells were transfected with WT T-bet or T-bet~Y304F~ mutant in the presence of a wild-type or T-bet mutant oligo. Oligo-bound proteins were immunoblotted for T-bet. (**f**) 293HEK cells were transfected with Myc-tagged Runx1, WT T-bet or T-bet~Y304F~ mutant in the presence of wild-type oligo, Runx1 mutant oligo or T-bet mutant oligo as indicated. Oligo-bound proteins were immunoblotted with anti-Myc and anti-T-bet antibodies. The data are representative of three independent experiments (**ad**) and one experiment (**e--f**).](nihms261541f7){#F7}

[^1]: Equal contribution
